当前位置:首页 >英文主页 >中英对照 > 中译版报告详情

美国商会:2023年创新药物可及性研究报告(中译版)(30页).pdf

上传人: Y**** 编号:156190 2023-12-22 30页 3.13MB

下载:

1、Patient Access Report2 2Table of ContentsExecutive Summary.4Introduction and Briefing Document Objective.7Measuring Biopharmaceutical Market Access Barriers.10Fewer Innovative Medicines and Longer Wait Times.16Conclusion.24Appendix.253The U.S.Chamber of Commerces Global Innovation Policy Center()is

2、working around the world to champion intellectual property rights as vital to creating jobs,saving lives,advancing global economic growth,and generating breakthrough solutions to global challenges.The U.S.Chamber of Commerce is the worlds largest business federation representing the interests of mor

3、e than 3 million businesses of all sizes,sectors,and regions,as well as state and local chambers and industry associations.This report was conducted by Pugatch Consilum,(www.pugatch-)a boutique consultancy that provides evidence-based research,analysis,and intelligence on the fastest growing sectors

4、 of the knowledge economy.Authors of this report are Meir Pugatch and David Torstensson.Professor Meir Pugatch,Managing Director and Founder|Prof.Pugatch is the Managing Director of Pugatch Consilium a boutique consultancy that provides evidence-based research,analysis and intelligence on the fastes

5、t growing sectors of the knowledge economy.He is an IPKM Professor of Valorisation,Entrepreneurship and Management at the University of Maastricht in the Netherlands;as well as a Professor at the School of Public Health,University of Haifa in Israel,in which he acts as the Chair of the Health Manage

6、ment Division since 2019.Prof.Pugatch specializes in innovation strategies,organizational entrepreneurship,intellectual property management,pharmacoeconomics,pricing and reimbursement,and the management of public health systems.He is the author and editor of an extensive number of publications and s

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要讨论了药品价格控制对创新药物市场准入的影响。报告由美国商会全球创新政策中心委托进行,由Pugatch Consilum公司撰写。报告分析了九个经合组织(OECD)成员国(澳大利亚、加拿大、法国、德国、意大利、日本、韩国、英国和美国)的药品市场准入情况,重点关注药品定价、报销和市场准入监管。 主要发现包括: 1. 大多数OECD国家广泛使用价格控制,而美国之前是唯一一个没有实施直接国家价格控制或以控制生物制药成本为目的政策的报告涵盖国家。 2. 使用价格控制的国家在生物制药产品上市数量上较少,包括生物制药和肿瘤药物。例如,过去20年美国上市的新生物制药中,只有49%在韩国上市,而澳大利亚只有38%。 3. 价格控制导致患者对新创新药物的获取延迟。例如,德国患者平均需要等待133天才能获得新治疗,西班牙则长达500天。 4. 2022年通过的通胀减免法案中的价格控制条款将对美国的生物制药创新产生不利影响,可能导致美国新药品和药物的开发和引入减少。 5. 政府官员在实施可能对患者和药品创新产生负面影响的定价控制政策时,应谨慎考虑其对患者、诉讼风险和其他实际问题的影响。
价格控制对药品创新有何影响? 新冠疫情如何改变药品市场? 药品价格控制对患者有何影响?
客服
商务合作
小程序
服务号
折叠